- Home
- INBX vs AURA Comparison
INBX vs AURA Comparison
Compare INBX & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- AURA
- Stock Information
- Founded
- INBX 2010
- AURA 2007
- Country
- INBX United States
- AURA United States
- Employees
- INBX N/A
- AURA N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- AURA Health Care
- Exchange
- INBX Nasdaq
- AURA Nasdaq
- Market Cap
- INBX 345.8M
- AURA 396.8M
- IPO Year
- INBX 2020
- AURA 2021
- Fundamental
- Price
- INBX $26.54
- AURA $6.10
- Analyst Decision
- INBX Hold
- AURA Strong Buy
- Analyst Count
- INBX 2
- AURA 7
- Target Price
- INBX N/A
- AURA $22.29
- AVG Volume (30 Days)
- INBX 112.9K
- AURA 172.4K
- Earning Date
- INBX 11-13-2025
- AURA 11-11-2025
- Dividend Yield
- INBX N/A
- AURA N/A
- EPS Growth
- INBX N/A
- AURA N/A
- EPS
- INBX N/A
- AURA N/A
- Revenue
- INBX $1,400,000.00
- AURA N/A
- Revenue This Year
- INBX N/A
- AURA N/A
- Revenue Next Year
- INBX N/A
- AURA N/A
- P/E Ratio
- INBX N/A
- AURA N/A
- Revenue Growth
- INBX N/A
- AURA N/A
- 52 Week Low
- INBX $10.81
- AURA $4.35
- 52 Week High
- INBX $30.23
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- INBX 52.65
- AURA 41.43
- Support Level
- INBX $27.51
- AURA $5.89
- Resistance Level
- INBX $28.86
- AURA $6.52
- Average True Range (ATR)
- INBX 1.38
- AURA 0.31
- MACD
- INBX -0.37
- AURA -0.03
- Stochastic Oscillator
- INBX 8.54
- AURA 25.27
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.